BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 36328157)

  • 21. Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) study.
    Cohen AT; Ay C; Hainaut P; Décousus H; Hoffmann U; Gaine S; Coppens M; da Silva PM; Castro DJ; Amann-Vesti B; Brüggenjürgen B; Levy P; Bastida JL; Vicaut E; Laeis P; Fronk EM; Zierhut W; Malzer T; Bramlage P; Agnelli G;
    Thromb J; 2018; 16():9. PubMed ID: 29719492
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies.
    Monagle P; Lensing AWA; Thelen K; Martinelli I; Male C; Santamaría A; Samochatova E; Kumar R; Holzhauer S; Saracco P; Simioni P; Robertson J; Grangl G; Halton J; Connor P; Young G; Molinari AC; Nowak-Göttl U; Kenet G; Kapsa S; Willmann S; Pap AF; Becka M; Twomey T; Beyer-Westendorf J; Prins MH; Kubitza D;
    Lancet Haematol; 2019 Oct; 6(10):e500-e509. PubMed ID: 31420317
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study.
    Brekelmans MP; Ageno W; Beenen LF; Brenner B; Buller HR; Chen CZ; Cohen AT; Grosso MA; Meyer G; Raskob G; Segers A; Vanassche T; Verhamme P; Wells PS; Zhang G; Weitz JI
    Lancet Haematol; 2016 Sep; 3(9):e437-45. PubMed ID: 27570090
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial.
    Male C; Lensing AWA; Palumbo JS; Kumar R; Nurmeev I; Hege K; Bonnet D; Connor P; Hooimeijer HL; Torres M; Chan AKC; Kenet G; Holzhauer S; Santamaría A; Amedro P; Chalmers E; Simioni P; Bhat RV; Yee DL; Lvova O; Beyer-Westendorf J; Biss TT; Martinelli I; Saracco P; Peters M; Kállay K; Gauger CA; Massicotte MP; Young G; Pap AF; Majumder M; Smith WT; Heubach JF; Berkowitz SD; Thelen K; Kubitza D; Crowther M; Prins MH; Monagle P;
    Lancet Haematol; 2020 Jan; 7(1):e18-e27. PubMed ID: 31699660
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ETNA-VTE Europe: Benefits and risks of venous thromboembolism treatment using edoxaban in the first 3 months.
    Agnelli G; Hoffmann U; Hainaut P; Gaine S; Ay C; Coppens M; Schindewolf M; Jimenez D; Brüggenjürgen B; Levy P; Laeis P; Fronk EM; Zierhut W; Malzer T; Manu MC; Reimitz PE; Bramlage P; Cohen AT;
    Thromb Res; 2020 Dec; 196():297-304. PubMed ID: 32950897
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Edoxaban Hokusai VTE PEDIATRICS Study: An open-label, multicenter, randomized study of edoxaban for pediatric venous thromboembolic disease.
    van Ommen CH; Albisetti M; Chan AK; Estepp J; Jaffray J; Kenet G; Young G; Dave J; Grosso MA; Duggal A
    Res Pract Thromb Haemost; 2020 Jul; 4(5):886-892. PubMed ID: 32685899
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Magnetic resonance venography to assess thrombus resolution with edoxaban monotherapy versus parenteral anticoagulation/warfarin for symptomatic deep vein thrombosis: A multicenter feasibility study.
    Piazza G; Mani V; Goldhaber SZ; Grosso MA; Mercuri M; Lanz HJ; Schussler S; Hsu C; Chinigo A; Ritchie B; Nadar V; Cannon K; Pullman J; Concha M; Schul M; Fayad ZA;
    Vasc Med; 2016 Aug; 21(4):361-8. PubMed ID: 27165711
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Routine clinical practice in the periprocedural management of edoxaban therapy is associated with low risk of bleeding and thromboembolic complications: The prospective, observational, and multinational EMIT-AF/VTE study.
    Colonna P; von Heymann C; Santamaria A; Saxena M; Vanassche T; Wolpert D; Laeis P; Wilkins R; Chen C; Unverdorben M
    Clin Cardiol; 2020 Jul; 43(7):769-780. PubMed ID: 32406557
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Editor's Choice - efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials.
    Kakkos SK; Kirkilesis GI; Tsolakis IA
    Eur J Vasc Endovasc Surg; 2014 Nov; 48(5):565-75. PubMed ID: 24951377
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of 15-mg Edoxaban on Clinical Outcomes in 3 Age Strata in Older Patients With Atrial Fibrillation: A Prespecified Subanalysis of the ELDERCARE-AF Randomized Clinical Trial.
    Kuroda M; Tamiya E; Nose T; Ogimoto A; Taura J; Imamura Y; Fukuzawa M; Hayashi T; Akao M; Yamashita T; Lip GYH; Okumura K
    JAMA Cardiol; 2022 Jun; 7(6):583-590. PubMed ID: 35416910
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The impact of renal function on clinical outcomes of patients with cancer-associated isolated distal deep vein thrombosis: Insights from the ONCO DVT study.
    Sueta D; Yamashita Y; Morimoto T; Muraoka N; Umetsu M; Nishimoto Y; Takada T; Ogihara Y; Nishikawa T; Ikeda N; Otsui K; Tsubata Y; Shoji M; Shikama A; Hosoi Y; Tanabe Y; Chatani R; Tsukahara K; Nakanishi N; Kim K; Ikeda S; Mo M; Kimura T; Tsujita K;
    Thromb Res; 2024 Mar; 235():107-115. PubMed ID: 38335565
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Compression stockings in addition to low-molecular-weight heparin to prevent venous thromboembolism in surgical inpatients requiring pharmacoprophylaxis: the GAPS non-inferiority RCT.
    Shalhoub J; Lawton R; Hudson J; Baker C; Bradbury A; Dhillon K; Everington T; Gohel MS; Hamady Z; Hunt BJ; Stansby G; Warwick D; Norrie J; Davies AH
    Health Technol Assess; 2020 Dec; 24(69):1-80. PubMed ID: 33275096
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Direct oral anticoagulants in the treatment of venous thromboembolism, with a focus on patients with pulmonary embolism: an evidence-based review.
    Gómez-Outes A; Suárez-Gea ML; Lecumberri R; Terleira-Fernández AI; Vargas-Castrillón E
    Vasc Health Risk Manag; 2014; 10():627-39. PubMed ID: 25404858
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial.
    Vranckx P; Valgimigli M; Eckardt L; Tijssen J; Lewalter T; Gargiulo G; Batushkin V; Campo G; Lysak Z; Vakaliuk I; Milewski K; Laeis P; Reimitz PE; Smolnik R; Zierhut W; Goette A
    Lancet; 2019 Oct; 394(10206):1335-1343. PubMed ID: 31492505
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and efficacy of edoxaban in patients undergoing hip fracture surgery.
    Fuji T; Fujita S; Kawai Y; Nakamura M; Kimura T; Kiuchi Y; Abe K; Tachibana S
    Thromb Res; 2014 Jun; 133(6):1016-22. PubMed ID: 24680549
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of New Oral Anticoagulants in the Treatment of Venous Thromboembolism and Thrombotic Prophylaxis.
    Akin M; Schäfer A; Akin I; Widder J; Brehm M
    Cardiovasc Hematol Disord Drug Targets; 2015; 15(2):92-6. PubMed ID: 26666324
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparing TEE- vs Non-TEE-guided cardioversion of atrial fibrillation: The ENSURE-AF trial.
    Kozieł M; Merino JL; De Caterina R; Huber K; Jin J; Melino M; Goette A; Lip GYH;
    Eur J Clin Invest; 2020 May; 50(5):e13221. PubMed ID: 32150758
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis.
    Sterne JA; Bodalia PN; Bryden PA; Davies PA; López-López JA; Okoli GN; Thom HH; Caldwell DM; Dias S; Eaton D; Higgins JP; Hollingworth W; Salisbury C; Savović J; Sofat R; Stephens-Boal A; Welton NJ; Hingorani AD
    Health Technol Assess; 2017 Mar; 21(9):1-386. PubMed ID: 28279251
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial.
    Lee AYY; Kamphuisen PW; Meyer G; Bauersachs R; Janas MS; Jarner MF; Khorana AA;
    JAMA; 2015 Aug; 314(7):677-686. PubMed ID: 26284719
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TropicALL study: Thromboprophylaxis in Children treated for Acute Lymphoblastic Leukemia with Low-molecular-weight heparin: a multicenter randomized controlled trial.
    Klaassen ILM; Lauw MN; van de Wetering MD; Biemond BJ; Middeldorp S; Abbink FCH; Bierings M; Te Loo DMMW; Pieters R; van der Sluis IM; Tissing WJE; Michel Zwaan C; Heleen van Ommen C
    BMC Pediatr; 2017 May; 17(1):122. PubMed ID: 28486976
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.